References
- Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948.
- Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159–165.
- Sibley MH, Mitchell JT, Becker SP. Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies. Lancet Psychiatry. 2016;3:1157–1165.
- Cortese S, Adamo N, Del GC, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727–738.
- NICE. ADHD Guidelines. cited 2019 Feb 23. Available from: https://www.nice.org.uk/guidance/NG87:
- Sunovion. A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years old with attention-deficit hyperactivity disorder (ADHD) in a simulated classroom setting. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03231800 NLM Identifier: NCT03231800.
- Sunovion. A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with attention-deficit hyperactivity disorder (ADHD) in a simulated classroom setting. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02734693 NLM Identifier: NCT02734693.
- Sunovion. Dasotraline pediatric ADHD study. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02428088 NLM Identifier: NCT02428088.
- Sunovion. Dasotraline adult ADHD study. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02276209 NLM Identifier: NCT02276209.
- Supernus Pharmaceuticals, Inc. Treatment of impulsive aggression (IA) in adolescent with ADHD in conjunction with standard ADHD treatment. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03597503 NLM Identifier: NCT03597503.
- Supernus Pharmaceuticals, Inc. Treatment of impulsive aggression in subjects with ADHD in conjunction with standard ADHD treatment (CHIME 1). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02618408 NLM Identifier: NCT02618408.
- Supernus Pharmaceuticals, Inc. Treatment of impulsive aggression in subjects with ADHD in conjunction with standard ADHD treatment (CHIME 2). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02618434 NLM Identifier: NCT02618434.
- Otsuka Pharmaceutical Development & Commercialization, Inc. A trial evaluating the efficacy, safety, & tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03605680 NLM Identifier: NCT03605680.
- Otsuka Pharmaceutical Development & Commercialization, Inc. A trial to evaluate the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03605836 NLM Identifier: NCT03605836.
- Neurovance, Inc. Safety and efficacy study of centanafadine sustained-release (CTN SR) in adults with attention-deficit hyperactivity disorder (ADHD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02547428 NLM Identifier: NCT02547428.
- Otsuka Pharmaceutical Development & Commercialization, Inc. The safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03324581 NLM Identifier: NCT03324581.
- Aevi Genomic Medicine. Efficacy and safety of NFC-1 in adolescents wth genetic disorders impacting mGluR and ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02777931 NLM Identifier: NCT02777931.
- Aevi Genomic Medicine. PART B: efficacy and safety of AEVI-001 in children and adolescents with ADHD and without mGluR mutations. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03609619 NLM Identifier: NCT03609619.
- Aevi Genomic Medicine. PART A: efficacy and safety of AEVI-001 in children and adolescents with ADHD and with mGluR mutations. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03265119 NLM Identifier: NCT03265119.
- Alcobra Ltd. Safety and tolerability study of metadoxine extended release (MDX) (previously known as MG01CI) in PI-ADHD adolescent subjects. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02189772 NLM Identifier: NCT02189772.
- Alcobra Ltd. A 6 week study of MG01CI 1400 mg compared with placebo in adults with ADHD (attention deficit/hyperactivity). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02059642 NLM Identifier: NCT02059642.
- NLS-1 Pharma Inc. Mazindol controlled release in adults with attention deficit hyperactivity disorder (ADHD). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02808104 NLM Identifier: NCT02808104.
- Lundbeck H A/S. Investigating the effect of vortioxetine in adult ADHD patients. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02327013 NLM Identifier: NCT02327013.
- Chiba University. Tipepidine in children with attention deficit/hyperactivity disorder (AD/HD): a double-blind, placebo-controlled trial. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02305134 NLM Identifier: NCT02305134.
- King’s College London; South London and Maudsley NHS Foundation Trust. Experimental medicine in ADHD – Cannabinoids (EMA-C). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02249299 NLM Identifier: NCT02249299.
- Alcobra Ltd. The MEASURE study – a phase 3 study of MDX 1400 mg daily compared with placebo in adults with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02477748 NLM Identifier: NCT02477748.
- Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER low dose in children with ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03247530 NLM Identifier: NCT03247530.
- Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER high dose in children with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03247543 NLM Identifier: NCT03247543.
- Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER low dose in adolescents with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03247517 NLM Identifier: NCT03247517.
- Supernus Pharmaceuticals, Inc. Evaluation of SPN-812 ER high dose in adolescents with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03247556 NLM Identifier: NCT03247556.
- Douglas Sears. A study of combination therapy in children with ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01940978 NLM Identifier: NCT01940978.
- Supernus Pharmaceuticals, Inc. Efficacy and safety of SPN-812 ER in children with ADHD. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02633527 NLM Identifier: NCT02633527.
- Massachusetts General Hospital. Oxytocin and cognitive control in Adult ADHD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2019 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT03136263
- 2019 [cited 2019 Feb 23]. Available from: https://www.pharmaceutical-business-review.com/clinical-trials/news/neurovances-centanafadine-adhd-drug-meets-main-goals-in-phase-2b-trial-4962886:
- Findling RL, Adler LA, Spencer TJ, et al. Dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol. 2019.
- 2019 [cited 2019 Feb 23]. Available from: https://www.cambridge.org/core/services/aop-cambridge-core/content/view/A4ABF5DF12C476CBC9CD08A168CE8733/S1092852918000627a.pdf/div-class-title-180-efficacy-of-dasotraline-in-children-with-attention-deficit-hyperactivity-disorder-in-a-laboratory-classroom-setting-div.pdf:
- 2019[cited 2019 Feb 23]. Available from: https://news.sunovion.com/press-release/sunovion-announces-top-line-results-studies-evaluating-dasotraline-adults-binge:
- 2019 [cited 2019 Feb 23]. Available from: http://ir.supernus.com/news-releases/news-release-details/supernus-announces-positive-results-phase-iii-study-spn-812:
- 2019 [cited 2019 Feb 23]. Available from: https://globenewswire.com/news-release/2018/12/06/1662924/0/en/Supernus-Announces-Positive-Results-from-Two-Phase-III-Studies-For-SPN-812-in-Children-with-ADHD.html:
- Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2019: 1087054719836159.
- Biederman J, Lindsten A, Sluth LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol. 2019;33:511–521.
- 2019 [cited 2019 Feb 23]. Available from: https://www.drugdevelopment-technology.com/news/aevi-reports-negative-results/:
- Elia J, Ungal G, Kao C, et al. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018;9:4.
- 2019 [cited 2019 Feb 23]. Available from: https://www.streetinsider.com/Corporate+News/Alcobra+%28ADHD%29+MDX+Phase+II+Met+Primary+Endpoint%3B+Secondary+Measures+Not+Statistically+Significant/10356002.html.
- 2019 [cited 2019 Feb 23]. Available from: http://deals.bio/index.php/home/download?doc_id=1082:
- [cited 2019 Jun 3]. Available from: https://www.genengnews.com/news/alcobra-adhd-candidate-mdx-fails-phase-iii-trial/
- Wigal TL, Newcorn JH, Handal N, et al. Study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD). CNS Drugs. 2018;32:289–301.
- Cortese S, Coghill D. Twenety years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Evid Based Ment Health. 2018;21:173–176.
- Tripp G, Wickens J. Reinforcement, dopamine and rodent models in drug development for ADHD. Neurotherapeutics. 2012;9:622–634.
- Cortese S, Holtmann M, Banaschewski T, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227–246.
- Finan C, Gaulton A, Kruger FA, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9(383).
- Wong I, Banaschewski T, Buitelaar J, et al. on behalf of the European ADHD guidelines group(EAGG. Emerging challenges in ADHD pharmacotherapy research – measures beyond symptom control and clinical trials outcome. Lancet Psychiatry. 2019;6(6):528–537.